ALKS : Summary for Alkermes plc - Yahoo Finance

U.S. Markets closed

Alkermes plc (ALKS)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
52.98+0.41 (+0.78%)
At close: 4:00PM EST
People also watch
ALXNINCYBMRNNBIXVRTX
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close52.57
Open52.20
Bid51.50 x 100
Ask0.00 x
Day's Range51.66 - 52.98
52 Week Range27.14 - 60.74
Volume505,380
Avg. Volume814,488
Market Cap8.05B
Beta2.33
PE Ratio (TTM)-38.39
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GuruFocus.com2 days ago

    Drug Addiction Treatment Stocks to Watch

    Big pharmaceutical companies are jockeying for the lead in this market

  • Alkermes Plc :ALKS-US: Earnings Analysis: 2016 By the Numbers : February 17, 2017
    Capital Cube8 days ago

    Alkermes Plc :ALKS-US: Earnings Analysis: 2016 By the Numbers : February 17, 2017

    Categories: Yahoo Finance Get free summary analysis Alkermes Plc reports financial results for the year ended December 31, 2016. We analyze the earnings along side the following peers of Alkermes Plc – Acorda Therapeutics, Inc., Bristol-Myers Squibb Company, Johnson & Johnson, Pfizer Inc., Astrazeneca PLC Sponsored ADR, Teva Pharmaceutical Industries Limited Sponsored ADR, Novartis AG Sponsored ADR and ... Read more (Read more...)

  • Alkermes (ALKS) Q4 Loss Narrower than Expectations, Sales Beat
    Zacks8 days ago

    Alkermes (ALKS) Q4 Loss Narrower than Expectations, Sales Beat

    Alkermes plc (ALKS) reported loss of 4 cents per share (including the impact of share-based compensation expense) in the fourth quarter of 2016, narrower than the Zacks Consensus Estimate of a loss of 19 cents.